Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

23.350
-0.050-0.21%
Volume:6.05M
Turnover:140.37M
Market Cap:20.36B
PE:68.24
High:23.950
Open:23.000
Low:22.300
Close:23.400
Loading ...

Hutchmed Completes Patient Enrollment in Phase II Gastric Cancer Trial in China

MT Newswires Live
·
22 Apr

- HUTCHMED China Ltd - HUTCHMED Completes Enrollment of Phase Ii Study

THOMSON REUTERS
·
22 Apr

Market Chatter: Hutchmed Looking Into Supply Chain Options for Blood Cancer Drug Amid US Tariffs

MT Newswires Live
·
15 Apr

Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment

MT Newswires Live
·
24 Mar

BRIEF-Hutchmed (China) Gets NMPA Conditional Approval For Tazverik® (Tazemetostat)

Reuters
·
21 Mar

Hutchmed Receives Conditional Approval for Tazverik as Follicular Lymphoma Treatment in China

MT Newswires Live
·
21 Mar

HUTCHMED (China) Ltd - Nmpa Conditional Approval for Tazverik® (Tazemetostat) for Treatment of Relapsed or Refractory Follicular Lymphoma

THOMSON REUTERS
·
21 Mar

HUTCHMED Announces Nmpa Conditional Approval for Tazverik® (Tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

THOMSON REUTERS
·
21 Mar

Hutchmed's Profit Falls in 2024

MT Newswires Live
·
20 Mar

Intended Retirement of Independent Non-Executive Directors and Changes of Composition of Board Committees

THOMSON REUTERS
·
20 Mar

HUTCHMED (China) Ltd - Savannah Phase Ii Trial Shows High Response Rates With Savolitinib Plus Tagrisso

THOMSON REUTERS
·
20 Mar

- HUTCHMED China Ltd - HUTCHMED Highlights Savolitinib Savannah Phase Ii

THOMSON REUTERS
·
20 Mar

BUZZ-HK-listed HUTCHMED jumps on 2024 profit beat

Reuters
·
20 Mar

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Benzinga
·
20 Mar

BRIEF-Hutchmed (China) Reports FY Net Income $ 37.7 Million

Reuters
·
19 Mar

Hutchmed's 2024 Earnings, Revenue Fall

MT Newswires Live
·
19 Mar

HUTCHMED Projects 2025 Oncology Revenue Between $350M–$450M, Backed By Strong Balance Sheet

Benzinga
·
19 Mar

HUTCHMED (China) FY 2024 GAAP EPS $0.22 Down From $0.58 YoY, Sales $630.20M Down From $838.00M YoY

Benzinga
·
19 Mar

HUTCHMED (China) Ltd: 2025 Outlook Oncology/Immunology Consolidated Revenue $350 Mln-$450 Mln

THOMSON REUTERS
·
19 Mar

HUTCHMED China Ltd - 2024 Final Results and Business Updates

THOMSON REUTERS
·
19 Mar